Use of TachoSil for durotomy repair in spine surgery: a single-center retrospective review
Neurosurgical Focus · 2025
DOI: 10.3171/2024.11.focus24667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurosurgical Focus, 2025. Verfasst von Rahul K Chaliparambil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of1Neurological Surgery and. Hauptthemen laut MEDLINE: Thrombin, Fibrinogen, Dura Mater, Cerebrospinal Fluid Leak. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 86 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE A significant complication of spine surgery is persistent postoperative CSF leak secondary to intentional or incidental durotomy. Traditionally, the gold standard for repair of simple durotomy has been primary surgical repair; however, this technique alone may not be possible for more complex durotomy and is often supplemented with sealants or fibrin glues. The authors add to the literature the largest series of spine surgery patients treated with TachoSil, a synthetic collagen patch containing human fibrinogen and human thrombin, for the management of incidental or intentional durotomy. METHODS The authors identified all patients who underwent a spinal operation and were billed for operative use of TachoSil at their institution between January 1, 2023, and November 3, 2023. Demographic, clinical, and outcome variables were collected and analyzed using standard statistical methods. Categorical variables were reported as number (%), and continuous variables were reported as median (range). RESULTS The authors retrieved 55 patients meeting their inclusion criteria. The population consisted of 29 (52.7%) females, had a median age of 52 years, and had a median BMI of 28.3 kg/m 2 . Of the repaired durotomies, 37 (67.3%) were intentional to the operation and 18 (32.7%) were incidental or secondary to trauma. Abnormal residual fluid collections were appreciated in 1 (1.8%) patient. Wound breakdown was observed in 2 (3.6%) patients. Thirty-day readmission was observed in 6 (10.9%) patients, and 30-day reoperation was necessary in 2 (3.6%) patients. Ninety-day readmission was observed in 7 (12.7%) patients and 90-day reoperation was necessary in 3 (5.5%) patients. One (1.8%) case of 30-day readmission was related to CSF leak, and no cases of 30-day or 90-day reoperation were related to dural closure failure. CONCLUSIONS This study is a brief examination of the demographic characteristics, surgical variables, and outcomes of durotomy repair in spine surgery with TachoSil and provides encouraging results for the continued use of the material in this context. This study provides the impetus for examination of TachoSil in larger, multi-institutional studies to establish it as a standard of care in spinal dural repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of1Neurological Surgery and.
- 2Orthopaedic Surgery, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Zitieren
APA
Chaliparambil, R. K., Kemeny, H. R., Mukherjee, S., Krushelnytskyy, M., Wolinksy, J. P., Swong, K., Dahdaleh, N. S., Ahuja, C. S., & El Tecle, N. E. (2025). Use of TachoSil for durotomy repair in spine surgery: a single-center retrospective review. Neurosurgical Focus. https://doi.org/10.3171/2024.11.focus24667
Vancouver
Chaliparambil RK, Kemeny HR, Mukherjee S, Krushelnytskyy M, Wolinksy JP, Swong K, et al. Use of TachoSil for durotomy repair in spine surgery: a single-center retrospective review. Neurosurgical Focus. 2025. doi:10.3171/2024.11.focus24667
BibTeX
@article{Chaliparambil2025,
author = {Chaliparambil, Rahul K and Kemeny, Hanna R and Mukherjee, Shreya and Krushelnytskyy, Mykhaylo and Wolinksy, Jean-Paul and Swong, Kevin and Dahdaleh, Nader S and Ahuja, Christopher S and El Tecle, Najib E},
title = {Use of TachoSil for durotomy repair in spine surgery: a single-center retrospective review},
journal = {Neurosurgical Focus},
year = {2025},
doi = {10.3171/2024.11.focus24667}
}
EUVIMED